A photo of Michael Gelfand.

Michael J. Gelfand, MD

  • Professor, UC Department of Radiology
  • UC Department of Pediatrics

About

Biography

Michael J. Gelfand, MD, received his BA from the University of Michigan and his MD from Stanford University. After two years at the National Institutes of Health, he completed residencies in pediatrics at Cincinnati Children's and nuclear medicine at the University of Cincinnati Medical Center.

Dr. Gelfand's research interests include I-123-MIBG imaging of neuroblastoma, new applications of hybrid imaging (PET/CT, SPECT/CT, PET/MRI) in pediatrics, and radiation dose reduction in nuclear medicine and hybrid imaging.

Dr. Gelfand has served as president of the Society of Nuclear Medicine, and served on the board of directors of that organization for 10 years.

Dr. Gelfand co-edited the textbooks Effective Use of Computers in Nuclear Medicine and Pediatric Nuclear Imaging. His publications include 126 journal articles and 31 book chapters. He has been an invited lecturer or visiting professor in France, Germany, the Netherlands, Italy, Argentina, Brazil, Japan and Australia.

BA: University of Michigan, Ann Arbor, MI, 1966.

MD: Stanford University, Stanford, CA, 1971.

Residency: Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 1973-1975, 1977; Nuclear Medicine, University of Cincinnati, Cincinnati, OH, 1975-1977.

Certification: Pediatrics, 1978; Nuclear Medicine, 1978.

Services and Specialties

Radiology, Epilepsy, Leukemia

Research Areas

Radiology

Publications

Differentiated Thyroid Cancer in the Pediatric/Adolescent Population: Evolution of Treatment. Remiker, AS; Chuang, J; Corathers, S; Rutter, MM; Rutter, MJ; Myer, CM; Gelfand, MJ; Trout, AT; Geller, JI. Journal of Pediatric Hematology/Oncology. 2019; 41:532-536.

Update: Image Gently and Nuclear Medicine at 10 Years. Treves, ST; Gelfand, M; Parisi, M; Lassmann, M; Goske, M; Sexton-Stallone, B; Fahey, F. Journal of Nuclear Medicine. 2019; 60:7N-9N.

Sentinel lymph node biopsy in head and neck rhabdomyosarcoma. Turpin, B; Pressey, JG; Nagarajan, R; Weiss, BD; Trout, AT; Gelfand, MJ; Pater, L; Vatner, RE; Breneman, JC; Dasgupta, R. Pediatric Blood and Cancer. 2019; 66.

A First Report of Secondary Hemophagocytic Lymphohistiocytosis Associated With Papillary Thyroid Carcinoma. Wakefield, C; Mehta, PA; Corathers, S; Geller, J; Gelfand, M; Olowokure, O; Marsh, RA. Journal of Pediatric Hematology/Oncology. 2018; 40:e97-e98.

Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1. Yanik, GA; Parisi, MT; Naranjo, A; Nadel, H; Gelfand, MJ; Park, JR; Ladenstein, RL; Poetschger, U; Boubaker, A; Valteau-Couanet, D; et al. Journal of Nuclear Medicine. 2018; 59:502-508.

Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials. Ladenstein, R; Lambert, B; Potschger, U; Castellani, M; Lewington, V; Bar-Sever, Z; Oudoux, A; Sliwinska, A; Taborska, K; Biassoni, L; et al. European Journal of Nuclear Medicine and Molecular Imaging. 2018; 45:292-305.

FDG PET/CT appearance of local osteosarcoma recurrences in pediatric patients. Sharp, SE; Shulkin, BL; Gelfand, MJ; McCarville, MB. Pediatric Radiology. 2017; 47:1800-1808.